Summit Securities Group LLC Acquires New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Summit Securities Group LLC bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 418 shares of the medical equipment provider’s stock, valued at approximately $37,000.

A number of other large investors have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new position in Lantheus during the third quarter worth $25,000. Kestra Investment Management LLC acquired a new position in shares of Lantheus during the 4th quarter valued at about $27,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the period. World Investment Advisors LLC acquired a new stake in shares of Lantheus during the 3rd quarter worth approximately $60,000. Finally, Parkside Financial Bank & Trust raised its position in Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is currently owned by insiders.

Lantheus Price Performance

NASDAQ:LNTH opened at $96.16 on Monday. Lantheus Holdings, Inc. has a 12 month low of $58.16 and a 12 month high of $126.89. The firm has a market capitalization of $6.59 billion, a PE ratio of 16.00 and a beta of 0.38. The business’s fifty day moving average price is $93.21 and its 200 day moving average price is $96.38.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on LNTH shares. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Finally, JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.